Quite strikingly, in our experiments, treatment with TrLp did indeed cause elimination of CD68high GBM cells in vivo, suppression of CD133+ GBM stem cells, and tumor remission in 50% of mice that originally harbored established GBM (Figures S3 and S6, Figure 4 and Figure 7) [14,21,22,28,32]. The gene discussed is PROM1; the disease is glioblastoma.